Dabigatran (Pradaxa)

Jules Comin; D. F. Kallmes

doi:10.3174/ajnr.A3000

Dabigatran (Pradaxa)

Jules Comin, D. F. Kallmes

Radiology

Research output: Contribution to journal › Short survey › peer-review

7 Scopus citations

Abstract

Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.

Original language	English (US)
Pages (from-to)	426-428
Number of pages	3
Journal	American Journal of Neuroradiology
Volume	33
Issue number	3
DOIs	https://doi.org/10.3174/ajnr.A3000
State	Published - Mar 2012

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Clinical Neurology

Access to Document

10.3174/ajnr.A3000

Cite this

@article{08e370b567f94213ac23bc8888fce788,

title = "Dabigatran (Pradaxa)",

abstract = "Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.",

author = "Jules Comin and Kallmes, {D. F.}",

year = "2012",

month = mar,

doi = "10.3174/ajnr.A3000",

language = "English (US)",

volume = "33",

pages = "426--428",

journal = "American Journal of Neuroradiology",

issn = "0195-6108",

publisher = "American Society of Neuroradiology",

number = "3",

}

TY - JOUR

T1 - Dabigatran (Pradaxa)

AU - Comin, Jules

AU - Kallmes, D. F.

PY - 2012/3

Y1 - 2012/3

N2 - Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.

AB - Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.

UR - http://www.scopus.com/inward/record.url?scp=84858671744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858671744&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A3000

DO - 10.3174/ajnr.A3000

M3 - Short survey

C2 - 22345499

AN - SCOPUS:84858671744

SN - 0195-6108

VL - 33

SP - 426

EP - 428

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

IS - 3

ER -

Dabigatran (Pradaxa)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this